Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项评价肤甘软膏治疗亚急性湿疹受试者的疗效和安全性的多中心,随机化,双盲,平行,安慰剂对照的II期研究
[Translation] A multicenter, randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of Fugan ointment in the treatment of subacute eczema subjects
使用EASI评分评估肤甘软膏用于轻到中度亚急性湿疹患者受损皮肤的疗效。
评估肤甘软膏在轻到中度亚急性湿疹受试者中应用的安全性和耐受性。
使用研究者总体评估(IGA)、总体严重程度评分(TSS)、瘙痒自我评分(VAS)和患者疾病控制的自我评价对肤甘软膏临床疗效进行评估。
[Translation] The EASI score was used to evaluate the efficacy of Fugan ointment on damaged skin in patients with mild to moderate subacute eczema.
To evaluate the safety and tolerability of Fugan ointment in subjects with mild to moderate subacute eczema.
The clinical efficacy of Fugan ointment was evaluated using the investigator's global assessment (IGA), total severity score (TSS), itch self-rating (VAS) and patient self-assessment of disease control.
100 Clinical Results associated with Chengdu Baiter Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Chengdu Baiter Pharmaceutical Co., Ltd.
100 Deals associated with Chengdu Baiter Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Chengdu Baiter Pharmaceutical Co., Ltd.